Corient Private Wealth
ANIP icon

Corient Private Wealth’s ANI Pharmaceuticals ANIP Stock Holding History

Corient Private Wealth’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2M Buy
24,106
+11,754
+95% +$943K ﹤0.01% 1402
2026
Q1 		$939K Buy
+12,352
New +$964K ﹤0.01% 1698

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Corient Private Wealth's ANIP Position: Q2 2026 in Review

Corient Private Wealth increased its ANI Pharmaceuticals (ANIP) stake by 95% in Q2 2026, buying an estimated $943K and bringing the position to 24,106 shares worth $2M. The position accounts for ﹤0.01% of the portfolio, ranked #1402.

Corient Private Wealth first reported a position in ANIP in Q1 2026 and has held it in 2 quarters since. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Corient Private Wealth held 24,106 shares of ANI Pharmaceuticals worth $2M as of Q2 2026.
  • Corient Private Wealth bought 11,754 ANI Pharmaceuticals shares in Q2 2026, an estimated $943K.
  • ANI Pharmaceuticals made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #1402 holding.
  • Corient Private Wealth first reported a position in ANI Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.